Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics

Pharmacogenetics and Genomics

Volumn 20, Issue 12, 2010, Pages 742-747

  Brisson, Diane ^a   Méthot, Julie ^a   Tremblay, Karine ^a   Tremblay, Monique ^a   Perron, Patrice ^a,b   Gaudet, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

apolipoprotein E; fibrates; genes; glycerol kinase; hypertriglyceridemia; lipoprotein lipase

Indexed keywords

APOLIPOPROTEIN E; FENOFIBRATE; GEMFIBROZIL; GLYCEROL KINASE; LIPID; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; XANTHOMA;

ADULT; CHOLESTEROL, HDL; FEMALE; FIBRIC ACIDS; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; PHENOTYPE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 78549293092     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328340095e     Document Type: Article

References (28)

1. Hegele RA, Ban MR, Hsueh N, Kennedy BA, Cao H, Zou GY, et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet 2009; 18:4189-4194.
2. Hegele RA, Pollex RL. Hypertriglyceridemia: phenomics and genomics. Mol Cell Biochem 2009; 326:35-43.
3. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176:1113-1120.
4. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008; 5:542-553.
5. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154:943-953.
6. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: what have we learned in the past 40 years? Pharmacotherapy 2007; 27:412-424.
7. Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, et al. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet 2008; 16:603-613.
8. Brisson D, Ledoux K, Bossé Y, St-Pierre J, Julien P, Perron P, et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 2002; 12:313-320.
9. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40:189-197.
10. Fredrickson DS, Levy RS, Lees RS. Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276:273-281.
11. Lohman T, Roche A, Martorel R. Standardization of anthropometric measurements. In: Lohman T, Roche A, Martorel R, editors. The airlie (VA) consensus conference. Champaign, IL: Human Kinetics; 1988.
12. Gaudet D, Arsenault S, Bélanger C, Hudson T, Perron P, Bernard M, et al. Procedure to protect confidentiality of familial data in community genetics and genomic research. Clin Genet 1999; 55:259-264.
13. Gaudet D, Arsenault S, Perusse L, Vohl MC, St-Pierre J, Bergeron J, et al. Glycerol as a correlate of impaired glucose tolerance: dissection of a complex system by use of a simple genetic trait. Am J Hum Genet 2000; 66:1558-1568.
14. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31:545-548.
15. Bijvoet SM, Hayden MR. Mismatch PCR: a rapid method to screen for the Pro207-Leu mutation in the lipoprotein lipase (LPL) gene. Hum Mol Genet 1992; 1:541.
16. Monsalve MV, Henderson H, Roederer G, Julien P, Deeb S, Kastelein JJ, et al. A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries. J Clin Invest 1990; 86:728-734.
17. De Bruin TW, Mailly F, Van Barlingen HH, Fisher R, Castro Cabezas M, Talmud P, et al. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia. Eur J Clin Invest 1996; 26:631-639.
18. Ma Y, Wilson BI, Bijvoet S, Henderson HE, Cramb E, Roederer G, et al. A missense mutation (Asp250Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. Genomics 1992; 13:649-653.
19. Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009; 122:962.e1-962.e8.
20. Sniderman AD, Hogue JC, Bergeron J, Gagné C, Couture P. Non-HDL cholesterol and apoB in dyslipidaemia. Clin Sci (Lond) 2008; 114:149-155.
21. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116:571-580.
22. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, et al. editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2789-2816.
23. Mahley RR, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, et al. editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2835-2862.
24. Ordovas JM, Mooser V. The APOE locus and the pharmacogenetics of lipid response. Curr Opin Lipidol 2002; 13:113-117.
25. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, et al. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther 2006; 11:211-221.
26. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622-630.
27. Richterich R. Clinical chemistry, theory and practice. 2nd ed. Basel, New York: Karger; 1969.
28. McCabe ER. Human glycerol kinase deficiency: an inborn error of compartmental metabolism. Biochem Med 1983; 30:215-230.